Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials (Q44730385)

5 December 2017

0 references

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials (English)

1 reference

5 December 2017

0 references

0 references

1

1 reference

5 December 2017

13

1 reference

5 December 2017

22

1 reference

5 December 2017

Margaret Piper

11

0 references

Kurt Schmidlin

object named as

Kurt Schmidlin

2

0 references

Marcel Zwahlen

object named as

Marcel Zwahlen

7

0 references

Mitchell Machtay

17

object named as

Mitchell Machtay

1 reference

5 December 2017

14

Benjamin Djulbegovic

1 reference

5 December 2017

12

Dirk Rades

1 reference

5 December 2017

20

Michael Untch

1 reference

5 December 2017

21

Martin Schumacher

1 reference

5 December 2017

16

Isabelle Ray-Coquard

1 reference

5 December 2017

6

Jerome Seidenfeld

1 reference

5 December 2017

4

Guido Schwarzer

1 reference

5 December 2017

9

Olaf Weingart

1 reference

5 December 2017

23

Andreas Engert

1 reference

5 December 2017

10

Sabine Kluge

1 reference

5 December 2017

15

Martin F Fey

1 reference

5 December 2017

18

Volker Moebus

1 reference

5 December 2017

Corinne Brillant

3

1 reference

5 December 2017

Sven Trelle

5

1 reference

5 December 2017

Michael Clarke

8

1 reference

5 December 2017

Gillian Thomas

19

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

5 December 2017

1 reference

5 December 2017

volume

373

1 reference

5 December 2017

issue

9674

1 reference

5 December 2017

page(s)

1532-1542

1 reference

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

ESAs further restricted, but debate continues

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Calculating the number needed to treat for trials where the outcome is time to an event

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Impact of epoetin beta on quality of life in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Erythropoietin for anaemia in cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Treatment resistance of solid tumors: role of hypoxia and anemia

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Mechanism of erythropoietin-induced hypertension

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Efficacy and safety of epoetin alfa in critically ill patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60502-X

7 January 2021

10.1016/S0140-6736(09)60502-X

Identifiers

DOI

1 reference

5 December 2017

1 reference